CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China

Yanfen Feng,Yu Zhang,Yuhua Huang,Yiyan Lei,Shaoyan Xi,Huilan Rao,Fang Wang,Jianyong Shao,Qiuliang Wu

doi:10.1186/s40880-017-0212-9

Abstract

BackgroundMature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive subtype with sporadic CD30 expression. However, the significance of CD30 expression in ENKTL is controversial. We aimed to classify a large cohort of patients with mature T-cell and NK-cell lymphomas according to the 2016 World Health Organization (WHO) classification guidelines and to study the association between CD30 expression and prognosis of patients with ENKTL.MethodsWe selected consecutive patients with mature T-cell and NK-cell lymphomas who attended our institution between September 1, 2009 and August 31, 2013. We classified the lymphomas according to the 2016 revision of the WHO classification of lymphoid neoplasms, analyzed the associations between CD30 expression and clinicopathologic features of ENKTL patients, and evaluated the prognostic implications of CD30 expression.ResultsWe identified 622 consecutive patients with mature T-cell and NK-cell lymphomas, including 317 (51.0%) patients with ENKTL. In addition, CD30 expression was detected in 43 (47.3%) of a subset of 91 patients with ENKTL. No clinicopathologic features were associated with CD30 expression, and CD30 positivity showed no prognostic significance in patients with ENKTL.ConclusionsENKTL is the most common type of mature T-cell and NK-cell lymphoma diagnosed at our institution. CD30 is frequently expressed in ENKTL and represents a therapeutic target; however, it may not be a prognostic marker.

Highlights

Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive subtype with sporadic CD30 expression
We previously reported that CD30 is expressed in ENKTL [8]; the significance of CD30 expression in ENKTL remains unclear
Subtype distribution In total, 622 patients with mature T-cell and NK-cell lymphomas were identified during the study period

Summary

Introduction

Mature T-cell and natural killer (NK)-cell lymphomas compose a heterogeneous group of non-Hodgkin lymphomas, and extranodal NK/T-cell lymphoma, nasal type (ENKTL) is an aggressive subtype with sporadic CD30 expression. We aimed to classify a large cohort of patients with mature T-cell and NK-cell lymphomas according to the 2016 World Health Organization (WHO) classification guidelines and to study the association between CD30 expression and prognosis of patients with ENKTL. According to the 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues, the most common subtypes of non-Hodgkin lymphoma. The recent availability of brentuximab vedotin, an anti-CD30 monoclonal antibody, has led to improved OS and FFS rates among patients with refractory Hodgkin lymphoma, which is characterized by strong and uniform expression of CD30 [6]. We previously reported that CD30 is expressed in ENKTL [8]; the significance of CD30 expression in ENKTL remains unclear

Objectives

Methods

Results

Conclusion